Please login to the form below

Not currently logged in
Email:
Password:

MISSION appoints Paul Wallace as chief business officer

Joins from Medivir where he was executive VP and head of business development

edit-Mission-Paul_WallaceCancer biotech MISSION Therapeutics has named Paul Wallace as chief business officer.

Wallace has worked in business development roles within drug discovery companies for almost 20 years, most recently at Medivir where he was executive VP and head of business development as well as member of the executive management team responsible for strategic and operational leadership, R&D portfolio management and investment planning.

Commenting on his appointment, Wallace said: “I am delighted to be joining the MISSION team at a time when the commercialisation of certain assets is an increasingly promising prospect.

“The diversity of assets created is testimony to the rigour of MISSION's screening platform in this critically important, but hitherto difficult, area of drug discovery.”

During his time at Medivir, he played a key role in the execution of over 25 partnership deals, eight products were taken into clinical development and two drugs were launched.

In his new role, Wallace will construct future business strategy, including the potential of development partnerships.

Anker Lundemose, MISSION CEO, added: “Paul's extensive business development experience will be invaluable in helping us find the right strategic partnerships to fully realise the potential of these assets.

“Our core focus is cancer, but our platform discovery approach has yielded highly promising molecules for other indications, such as Parkinson's disease. We see partnering as an attractive option for taking these non-core projects forward.”

17th March 2015

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics